BLUE - bluebird bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
BLUE price evolution
BLUE
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.06 | $1.3 | $0.97 | |
| Inventory | $53.94 | $33.33 | $30.3 | $22.92 |
| Total current assets | $150.81 | $203.52 | $271.6 | $281.69 |
| Long term investments | ||||
| Property, plant & equipment | $245.69 | $267.96 | $285.57 | $267.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $465.06 | $545.19 | $631.48 | $619.16 |
| Current liabilities | ||||
| Accounts payable | $24.48 | $30.59 | $19.39 | $18.5 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $296.03 | $297.93 | $293.57 | $200.11 |
| Long term debt | $5.67 | $19.66 | $26.09 | $37.73 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $470.84 | $492.21 | $500.44 | $424.62 |
| Shareholders' equity | ||||
| Retained earnings | -$4472.33 | -$4411.52 | -$4330.13 | -$4260.33 |
| Other shareholder equity | -$1.51 | -$2.12 | -$2.11 | -$1.8 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.01 | $161.16 | $317.7 | |
| Short term investments | $67.32 | $138.34 | $833.55 | |
| Net receivables | $10.79 | $11.39 | $26.81 | |
| Inventory | $22.92 | |||
| Total current assets | $281.69 | $199.49 | $336.52 | $1215.54 |
| Long term investments | $1.41 | $97.11 | $122.89 | |
| Property, plant & equipment | $267.05 | $291.36 | $101.24 | $346.85 |
| Goodwill & intangible assets | $10.51 | $5.65 | $23.17 | |
| Total noncurrent assets | $355.41 | $257.27 | $565.72 | |
| Total investments | $68.73 | $235.46 | $956.44 | |
| Total assets | $619.16 | $554.9 | $593.79 | $1781.25 |
| Current liabilities | ||||
| Accounts payable | $18.5 | $25.09 | $25.88 | $21.6 |
| Deferred revenue | $28.08 | |||
| Short long term debt | $51.16 | $23.15 | $25.02 | |
| Total current liabilities | $200.11 | $128.24 | $152.99 | $203.59 |
| Long term debt | $37.73 | $230.23 | $66.43 | $168 |
| Total noncurrent liabilities | $230.32 | $66.53 | $222.61 | |
| Total debt | $281.39 | $89.58 | $193.02 | |
| Total liabilities | $424.62 | $358.56 | $219.52 | $426.2 |
| Shareholders' equity | ||||
| Retained earnings | -$4260.33 | -$3986.5 | -$3719.93 | -$2900.55 |
| Other shareholder equity | -$1.8 | -$4.07 | -$2.91 | -$5.5 |
| Total shareholder equity | $196.34 | $374.28 | $1355.06 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.61 | $7.83 | ||
| Cost of revenue | ||||
| Gross Profit | -$1.17 | -$1.8 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $62.94 | $80.88 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.06 | -$0.05 | ||
| Interest expense | -$4.14 | -$14.44 | ||
| Net income | ||||
| Net income | -$60.81 | -$88.51 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $29.5 | $3.6 | $3.66 | $250.73 |
| Cost of revenue | $10.08 | $38.86 | $5.4 | |
| Gross Profit | -$4.03 | -$6.48 | -$35.2 | $245.34 |
| Operating activities | ||||
| Research & development | $240.76 | $319.95 | $587.96 | |
| Selling, general & administrative | $136.91 | $209.97 | $286.9 | |
| Total operating expenses | $333.16 | $280.61 | $555.72 | $874.85 |
| Operating income | -$287.09 | -$590.91 | -$629.51 | |
| Income from continuing operations | ||||
| EBIT | -$267.49 | -$820 | -$629.55 | |
| Income tax expense | -$0.13 | $0.12 | $0.26 | $0.69 |
| Interest expense | -$6.48 | -$1.03 | -$0.88 | -$11.54 |
| Net income | ||||
| Net income | -$211.91 | -$266.58 | -$819.38 | -$618.7 |
| Income (for common shares) | -$266.58 | -$819.38 | -$618.7 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1.43 | $0.97 | -$0.66 | $154.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $52.48 | $58.58 | $64.64 | $196.25 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$155.94 | -$81.38 | -$10.69 | $116.15 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$266.58 | -$819.38 | -$618.7 | |
| Operating activities | ||||
| Depreciation | $5 | $19.65 | $19.36 | |
| Business acquisitions & disposals | $110.3 | |||
| Stock-based compensation | $35.19 | $127.92 | $156.63 | |
| Total cash flows from operations | -$352.95 | -$635.64 | -$470.35 | |
| Investing activities | ||||
| Capital expenditures | $93.79 | -$14.5 | -$28.99 | |
| Investments | $161.66 | $475.26 | -$55.36 | |
| Total cash flows from investing | $154.95 | $250.45 | $562.56 | -$84.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $54.25 | $80.33 | $546.72 | |
| Net borrowings | ||||
| Total cash flows from financing | $196.25 | $54.25 | -$93.95 | $546.72 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $116.15 | -$48.25 | -$167.04 | -$7.98 |
News
Fundamentals
| Market cap | $975.40M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 193.92M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -14.36% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.51 |
| Quick ratio | 0.33 |